The impact of drug therapy on quality of life in headache and migraine

PharmacoEconomics

Volumn 11, Issue 4, 1997, Pages 334-342

  Solomon, Glen D ^a   Litaker, David G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; DICLOFENAC; FLURBIPROFEN; SUMATRIPTAN;

CHRONIC DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; EMOTION; HEADACHE; HEALTH CARE COST; HUMAN; MEDICAL LITERATURE; MIGRAINE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; TREATMENT OUTCOME;

EID: 0030980695     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711040-00004     Document Type: Review

References (40)

1. Ries PW. Current estimates from the national health interview survey, United States, 1984. National Center for Health Statistics; 1986 Vital and Health Statistics. Series 10, No. 156, Department of Health and Human Services Publications. 86-1584
2. Clouse JC, Osterhaus JT, Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994; 28: 659-664
3. Stewart WK, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992; 267: 64-9
4. Edmeads J, Findlay H, Tugwell P, et al. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993; 20: 131-7
5. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the medical outcomes study. JAMA 1989; 262: 907-13
6. Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well being of headache patients: measurement by the Medical Outcomes Study Instrument. Headache 1993; 33: 351-8
7. Solomon GD, Skobieranda FG, Gragg LA. Does quality of life differ among headache diagnoses? Analysis using the Medical Outcomes Study Instrument. Headache 1994; 34: 143-7
8. Skobieranda FG, Solomon GD, Gragg LA. Quality of life changes in headache patients following six months of outpatient treatment: use of the Medical Outcomes Study Instrument [abstract]. Headache 1993; 33: 283
9. Tarlov AR, Ware JE, Greenfield S, et al. The medical outcomes study: an application of methods for monitoring the results of medical care. JAMA 1989; 262: 925-30
10. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724-35
11. Osterhaus JT, Townsend RJ. The quality of life of migraineurs: a cross sectional profile [abstract]. Cephalalgia 1991; 11 Suppl. 11: 103-4
12. Miller DW, Osterhaus JT, Hirsh JD, et al. Quality of life assessment among migraineurs treated with sumatriptan: preliminary findings [abstract]. Headache 1993; 33: 278
13. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short form health survey (SF-36). II: psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63
14. Dahlöf C, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995 Feb; 15: 31-6
15. Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache 1994 Jun; 34: 337-43
16. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 1989; 262: 914-9
17. Osterhaus JT, Miller DW. The burden of migraine [abstract]. Headache 1993; 33: 279
18. Kozma CM, Mauch RP, Reeder CE, et al. A literature review comparing the economic, clinical, and humanistic attributes of dihydroergotamine und sumatriptan. Clin Ther 1994 NovDec; 16(6): 1037-51
19. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67-76
20. Osterhaus JT, Stang PE. Migraine headache and the 1989 National Health Interview Survey: utilization and impact [abstract]. Headache 1992; 32: 265
21. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993; 13: 117-23
22. Dahlöf C. Health-related quality of life under six months treatment of migraine - an open clinic-based longitudinal study. Cephalalgia 1995; 15: 414-22
23. Dahlöf C. Flunarizine versus long-acting propranolol in the prophylactic treatment of migraine: a dotihle blind parallel group study. In: Rose FC, editor. New advances in headache research. London: Smith-Gordon, 1989: 281-9
24. Solomon GD, Kunkel RS. Long-term use of flurbiprofen in migraine prophylaxis [abstract]. Headache 1992; 32: 269-70
25. Solomon GD, Nielson K, Miller D. The effects of sumatriptan on migraine: health related quality of life. Med Interface 1995 Jun; 8 (6): 134-41
26. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995 Sep; 35: 449-54
27. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health related quality of life among hospital employees with migraine. Headache 1996; 36: 137-43
28. Beall D, Cohen J, Miller D, et al. An interim analysis of the use of subcutaneous sumatriptan in a managed care setting: effects on health-related quality of life, impact on health care resource use, and clinical efficacy [abstract]. Pharmacotherapy 1995 May-Jim; 15: 385
29. Adelman J, Sharfman M, Johnson R, et al. Impact of oral sumatriptan on health-related quality of life and productivity in health care professionals with migraine: an interim analysis [abstract]. Pharmacotherapy 1995 May-Jun; 15: 387
30. Bullinger M, Bruggenjurgen B. Quality of life assessment among migraineurs under current treatment and after three months treatment with sumatriptan. Poster presented at the European Federation of Neurological Societies: 1993 Dec; Berlin
31. D'allens H, Richard A, Bertin L, et al. Responsiveness assessment of a specific quality of life questionnaire for migraineurs (QVM) [abstract]. Qual Life Res 1994 Feb; 3: 72
32. Scopp AL, Peters KS. Patient rating of trigger elimination eftectiveness in comprehensive migraine treatment program [abstract]. Headache 1992; 32: 269
33. VandenBree MB, Passchier J, Emmen HH. Influence of quality of life and stress coping behaviour on headaches in adolescent male students: an explorative study. Headache 1990 Feb; 30 (3): 165-8
34. Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on care utilization and costs of care in migraineurs. Headache 1996; 36: 538-41
35. Cohen JA, Beall DG, Beck A, et al. Use of sumatriptan to treat migraines in a group model HMO: health care use, health related quality of life, and clinical effectiveness [abstract]. Neurology 1996; 46: A322-3
36. Bosanquet N, Zammit-Lucia J. Migraine: prevention or cure? Br J Med econ 1992; 2: 81-91
37. Gross MLP, Dowson AJ, Deavy L. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br J Med Econ 1996; 10: 231-46
38. Solomon GD, Litaker D, Genzen JR. Use of clinical features to predict response to sumatriptan in migraine [abstract]. Neurology 1996; 46: A323-4
39. Barnat MR, Lake AE. Patient altitudes about headache. Headache 1983 Sep; 23 (5): 229-37
40. Ware JE, Snow KK, Kosinski M, et al., editors. SF-36 Health Survey: Manual and Interpretation Guide. Boston (MA): The Health Institute. New England Medical Center, 1993